Message from the CEO
Sydney, Aug 30, 2019 AEST (ABN Newswire) - The 2018-2019 year has been a year of transition for Anatara Lifesciences (
ASX:ANR), having commenced the year with a clear focus on successfully evolving into a human health company, through the pursuit of the burgeoning gastrointestinal health market.
I continue to believe that our innovative Gastrointestinal ReProgramming (GaRP) dietary supplement has an opportunity to 'change the game' in the treatment of gastrointestinal conditions such as Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD).
In the past two months, I have had the opportunity to present to audiences at the Bioshares Biotech Summit in New Zealand and at the Monsoon Communications Twilight Investor Briefing in Melbourne last week. During my presentations, I highlighted why gut health and the microbiome are changing medicine, and where we sit in the treatment landscape. I have spoken previously about the significant unmet need for evidence-based complementary medicines in gastrointestinal health, with up to 50% of IBS and IBD patients turning to supplements and complementary and alternative medicines to seek additional therapeutic relief. The impact of IBS and IBD on a patients' quality of life is devastating, coupled with the huge costs to society in terms of direct medical costs and work absenteeism - $21 Billion or more annually, according to the International Foundation for Gastrointestinal Disorders.
Anatara's GaRP dietary supplement has been uniquely designed to address the primary underlying factors of these conditions and over the coming months, you will hear more about GaRP's triple-targeted therapeutic approach, exhibiting anti-adhesion, anti-inflammatory and mucosal regeneration effects.
Our pre-clinical animal studies in IBD are ongoing, with initiation of a human clinical study in IBS to follow in late 2019. We expect that the results from these studies will not only reassure patients and clinicians that GaRP is safe and effective, but also place Anatara in a better negotiating position with potential partners, where I look forward to putting my many years of successful business development experience to work.
Pivoting to our animal health business; we announced in June that Zoetis would no longer continue as a strategic partner for our animal health assets, the Company remains confident that a substantial market opportunity for Detach(R) exists, with more pressure than ever on producers to reduce their antibiotic use and find suitable alternatives which minimise illnesses, such as scour, on farms.
I would like to again thank shareholders for their continued patience and support of the Company as we continue to execute on the strategic re-partnering of Detach(R) and the further clinical development of our breakthrough GaRP dietary supplement, which we believe will deliver much-needed relief for IBS and IBD patients and drive value for our shareholders.
I look forward to keeping you updated on our progress in the coming months.
Steven Lydeamore
Chief Executive Officer
slydeamore@anatara.com
About Anatara Lifesciences Limited
Anatara Lifesciences Limited (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing productsfor human and animal health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.
| ||
|
